Kena Betancur | Corbis News | Getty Images Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury
Kena Betancur | Corbis News | Getty Images Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury